Dr Robert Clarke and his team at the University's Cancer Studies research group have been investigating human breast cancers for the presence of stem cells - cells that generate new tumours and can cause the cancer to recur - in a series of studies funded by the charity Breast Cancer Campaign.
One third of women who are successfully treated for breast cancer find that the disease recurs some years later because some of these cancer cells survive the treatment and begin to grow again.
The team's research into these `breast cancer stem cells' revealed that the cells are stimulated by the Notch gene. The team, who published the study in Journal of the National Cancer Institute, is now hoping to develop new drug therapies to target this gene and thus stop the growth of any surviving breast cancer stem cells.
One drug that is known to attack Notch is already used for the treatment of Alzheimer's Disease so, having undergone health and safety checks, its clinical trial for use on breast cancer patients could be speeded up and lead to a treatment in hospital clinics within a few years. Herceptin, by contrast, took more than 15 years to go from the discovery of its gene target to treatment.
The team is also aiming to identify other new pathways of controlling breast cancer stem cells by using a genetic library to shut down other genes at random to see how it affects them, in a study with Rene Bernards at the Netherlands Cancer Institute.
The team, along with Professor Tony Whetton, are using a state-of-the-art mass-spectrometry based proteomics facility at the Paterson Institute of Cancer Research to identify proteins that control breast cancer stem cells. The facility - one of only a few in the UK - enables them to break up breast cancer stem cell proteins and analyse the sequence of amino acids to identify novel proteins that control the cells' growth.
Dr Clarke says: "Our work has revealed the importance of several pathways not previously known to regulate stem cell survival and self-renewal, which is tremendously exciting. Inhibitors of signalling pathways that regulate cancer stem cells could represent a new therapeutic modality in breast cancer, to be used in combination with current treatments in the near future."
Jon Keighren | alfa
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine